Eli Lilly and Company
LLYNYSE
$1,294.35
Last price · USD
- Market cap
- $1.16T
- P/E
- 56.4x
- EV / EBITDA
- 37.8x
- P/S
- 17.8x
- FCF yield
- 0.8%
- Div. yield
- 0.46%
Multiples use last price and FY2025 annual figures. Market cap estimated from diluted shares.
Eli Lilly and Company cash flow statement
Annual · USD millions except per-share data · 34 lines
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | CAGR | |
|---|---|---|---|---|---|---|---|
| Operating activities | |||||||
| Net income | 20,640 | 10,590 | 5,240 | 6,245 | 5,582 | +38.7% | |
| Depreciation & amortization | 1,997 | 1,767 | 1,527 | 1,523 | 1,548 | +6.6% | |
| Deferred income tax | (1,707) | (2,683) | (2,341) | (2,185) | (802) | — | |
| Stock-based compensation | 626 | 646 | 629 | 371 | 343 | +16.2% | |
| Change in working capital | (8,093) | (5,385) | (3,055) | (1) | (1,013) | — | |
| Accounts receivables | (7,000) | (2,155) | (2,451) | (300) | (1,278) | — | |
| Inventory | (4,671) | (2,507) | (1,425) | (600) | (236) | — | |
| Accounts payables | 10,187 | 2,609 | 4,274 | 1,332 | (1,014) | — | |
| Other working capital | (6,609) | (3,331) | (3,453) | (433) | 1,515 | — | |
| Other non-cash items | 3,350 | 3,884 | 2,240 | 1,633 | 1,709 | +18.3% | |
| Net cash from operating activities | 16,813 | 8,818 | 4,240 | 7,586 | 7,366 | +22.9% | |
| Operating cash flow | 16,813 | 8,818 | 4,240 | 7,586 | 7,366 | +22.9% | |
| Investing activities | |||||||
| Investments in PP&E | (7,841) | (8,404) | (3,448) | (1,854) | (1,310) | — | |
| Capital expenditure | (7,841) | (5,058) | (7,392) | (2,985) | (1,978) | — | |
| Acquisitions, net | (661) | (948) | (1,044) | (327) | (747) | — | |
| Purchases of investments | (645) | (776) | (829) | (708) | (1,013) | — | |
| Sales / maturities of investments | 964 | 523 | 700 | 464 | 847 | +3.3% | |
| Other investing activities | (2,789) | 303 | (2,532) | (1,337) | (644) | — | |
| Net cash from investing activities | (10,972) | (9,301) | (7,153) | (3,763) | (2,867) | — | |
| Financing activities | |||||||
| Net debt issuance | 8,051 | 8,901 | 8,650 | (62) | 501 | +100.2% | |
| Short-term net debt issuance | (4,338) | (1,852) | 4,691 | 1,498 | (4) | — | |
| Long-term net debt issuance | 12,389 | 10,753 | 3,959 | (1,560) | 505 | +122.5% | |
| Net stock issuance | (4,108) | (2,500) | (750) | (1,500) | (1,250) | — | |
| Common stock repurchased | (4,108) | (2,500) | (750) | (1,500) | (1,250) | — | |
| Net common stock issuance | (4,108) | (2,500) | (750) | (1,500) | (1,250) | — | |
| Common dividends paid | (5,384) | (4,680) | (4,069) | (3,536) | (3,087) | — | |
| Net dividends paid | (5,384) | (4,680) | (4,069) | (3,536) | (3,087) | — | |
| Other financing activities | (772) | (491) | (335) | (309) | (296) | — | |
| Net cash from financing activities | (2,213) | 1,230 | 3,496 | (5,407) | (4,131) | — | |
| Cash summary | |||||||
| Effect of forex changes on cash | 372 | (297) | 169 | (168) | (206) | — | |
| Net change in cash | 4,000 | 450 | 752 | (1,751) | 161 | +123.1% | |
| Cash at beginning of period | 3,268 | 2,819 | 2,067 | 3,819 | 3,657 | -2.8% | |
| Cash at end of period | 7,268 | 3,268 | 2,819 | 2,067 | 3,819 | +17.5% | |
| Free cash flow | 8,972 | 3,760 | (3,152) | 4,600 | 5,388 | +13.6% | |